Primary cutaneous amyloidosis
Conditions
Interventions
Observation group(Tofacitinib citrate tablets combined with acitretin capsules):None
Control group(acitretin capsules):None
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old, free from infectious diseases such as hepatitis B and tuberculosis and major underlying diseases (gender not limited); 2.The outpatient diagnosis includes "primary cutaneous amyloidosis" or "macular amyloidosis" or "lichen amyloidosis"; 3.Because PCA has visited the clinic 4 times or more; 4.The medication record shows "Avita Capsules" and/or "Tofacitinib Citrate"; 5.The medical record comprehensively records the baseline characteristics, dosage of medication, efficacy assessment, and adverse events.
Exclusion criteria
Exclusion criteria: 1.Nodular amyloidosis or combined with other types of amyloidosis (such as systemic amyloidosis); 2.During the study period, other immunosuppressants (such as glucocorticoids, methotrexate) or biologics were used; 3.The medical records, including demographic data, laboratory parameters, prescription administration, and the patient's prognosis, are incomplete, and the treatment was not standardized.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The composite clinical response rate for the 12th week; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrent rate in the 24th week;Incidence rate of adverse events;Change in the area of skin lesions;Changes in peak pruritus scores at different time points;Achieve an IGA 0/1 (complete or nearly complete) ratio; | — |
Countries
China
Contacts
Public ContactYin Rui
The First Affiliated Hospital of Army Medical University
Outcome results
None listed